We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effective Neutralization of Daratumumab Effects on Pre-Transfusion Testing: a Method Modification.
- Authors
Feldman, Anna; Duek, Adrian M.; Mandel-Benado, Mathilda; Cohen, Liz A.; Feldman, Daniel R.; Leiba, Merav
- Abstract
Background: The anti-CD38 antibody daratumumab is a common multiple myeloma treatment. As the erythrocyte's membrane expresses CD38, Daratumumab-treated samples show agglutination in serological pre-transfusion tests, hindering detection of erythrocyte alloantibodies. Dithiothreitol interferes with erythrocyte antigens, affecting investigation of unexpected antibodies. DARAEx®, an anti-CD38 neutralizing agent, overcomes daratumumab- induced effects, without dithiothreitol's interferences. DARAEx® is applied only in Biorad columns. This study aimed to provide a DARAEx® protocol for application with the Grifols platform. Methods: We introduced a modified DARAEx® protocol (AssutaBB protocol) and performed antibody screenings on samples from nineteen daratumumab-treated patients. Results: The AssutaBB protocol provided antibody screen results for all patients, exactly as established in the default manufacturing protocol. Eleven patients presented natural negative antibody screens; eight presented positive K/E antibodies. Conclusions: AssutaBB allows the use of the more widespread Grifols platform in daratumumab-treated patients.
- Publication
Clinical Laboratory, 2022, Vol 68, Issue 9, p1977
- ISSN
1433-6510
- Publication type
Academic Journal
- DOI
10.7754/Clin.Lab.2022.211243